Lyka Labs Limited Stock Price Today (NSE: LYKALABS)
Fundamental Score
Lyka Labs Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Lyka Labs Limited share price today is ₹80.11, down 1.40% on NSE/BSE as of 16 September 2026. Lyka Labs Limited (LYKALABS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹289.62 (Cr). The 52-week high for LYKALABS share price is ₹101.90 and the 52-week low is ₹44.10. The company has a Return on Equity (ROE) of -10.24% and a debt-to-equity ratio of 0.52.
Lyka Labs Limited Share Price Chart — NSE/BSE Historical Performance
Lyka Labs Limited share price chart: 19.74% return over the past month. 52-week high ₹101.90, 52-week low ₹44.10.
Lyka Labs Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹80.00 | ₹80.11 | ₹79.90 | ₹80.11 | 10.55K (Cr) | |
| ₹82.50 | ₹82.50 | ₹81.25 | ₹81.25 | 3.89K (Cr) | |
| ₹84.00 | ₹84.00 | ₹82.80 | ₹82.90 | 8.27K (Cr) | |
| ₹83.21 | ₹84.80 | ₹83.21 | ₹84.20 | 48.87K (Cr) | |
| ₹83.14 | ₹83.14 | ₹83.14 | ₹83.14 | 26.23K (Cr) | |
| ₹81.51 | ₹81.51 | ₹81.50 | ₹81.51 | 45.25K (Cr) | |
| ₹79.92 | ₹79.92 | ₹79.91 | ₹79.92 | 11.49K (Cr) | |
| ₹78.36 | ₹78.36 | ₹78.36 | ₹78.36 | 31.84K (Cr) | |
| ₹75.00 | ₹76.83 | ₹73.90 | ₹76.83 | 23.07K (Cr) | |
| ₹73.00 | ₹75.33 | ₹73.00 | ₹75.33 | 15.30K (Cr) |
Lyka Labs Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹75.36 | ₹84.80 | ₹73.00 | ₹80.11 | +6.30% | |
| ₹60.80 | ₹76.58 | ₹60.30 | ₹75.36 | +23.95% | |
| ₹74.81 | ₹77.00 | ₹58.00 | ₹60.80 | -18.73% | |
| ₹60.48 | ₹77.05 | ₹54.65 | ₹73.95 | +22.27% | |
| ₹59.75 | ₹67.99 | ₹57.00 | ₹58.30 | -2.43% | |
| ₹45.80 | ₹61.99 | ₹45.80 | ₹59.70 | +30.35% | |
| ₹62.08 | ₹62.38 | ₹44.10 | ₹44.95 | -27.59% | |
| ₹72.30 | ₹73.85 | ₹60.20 | ₹62.35 | -13.76% | |
| ₹75.10 | ₹84.70 | ₹70.21 | ₹71.74 | -4.47% | |
| ₹79.99 | ₹86.90 | ₹72.20 | ₹75.89 | -5.13% | |
| ₹94.04 | ₹96.00 | ₹79.06 | ₹80.42 | -14.48% | |
| ₹96.67 | ₹100.94 | ₹91.58 | ₹94.04 | -2.72% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Lyka Labs Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lyka Labs Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LYKALABS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (18.61%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (107.31%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (28.11%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Cash Generation (₹45.40 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (58.16%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-10.24%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-6.75%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Weak Earnings Growth (4.19% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (0.77% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (-2.54x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Limited Institutional Interest (FII+DII: 0.95%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Lyka Labs Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Lyka Labs Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Lyka Labs LimitedLyka Labs Limit...Selected✓ LYKALABS • 500259 | 18.9/100 | ₹80.11₹80 | ₹289.62₹289.62 | — — | -10.24%Poor -10.24% Poor | -6.75%Poor -6.75% Poor | 0.52Good 0.5 Good | 0.77%Average 0.77% Average | 8.29%Good 8.29% Good | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9425.50₹9426 | ₹249775.75₹249775.75 | 85.52Average 85.5 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4927.00₹4927 | ₹166759.24₹166759.24 | 78.71Average 78.7 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.00₹1370 | ₹110675.45₹110675.45 | 32.82Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1925.50₹1926 | ₹104025.14₹104025.14 | 95.04Average 95.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1675.20₹1675 | ₹96391.01₹96391.01 | 26.17Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2099.90₹2100 | ₹96017.92₹96017.92 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1141.40₹1141 | ₹95306.90₹95306.90 | 29.50Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2289.10₹2289 | ₹94539.83₹94539.83 | 46.25Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price249775.75 Cr
- Torrent Pharmaceuticals Limited share price166759.24 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110675.45 Cr
Lyka Labs Limited PE Ratio History
Historical price-to-earnings ratio for LYKALABS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹2.25 | ₹75.89 | 33.7x |
| FY 2022 | ₹13.57 | ₹129.70 | 9.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Lyka Labs Limited Quarterly Performance
Latest quarterly metrics for LYKALABS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
28.11%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
107.31%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
8.29%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
0.77%
Compounded annual net profit growth over 5 years
Lyka Labs Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LYKALABS — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Lyka Labs Limited Financial Statements
Annual income statement, balance sheet and cash flow for Lyka Labs Limited (LYKALABS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Lyka Labs Limited
About LYKALABS (Lyka Labs Limited)
Lyka Labs Ltd is a dynamic pharmaceutical entity deeply rooted in the Indian landscape, operating at the intersection of innovative drug development and robust manufacturing practi...ces. With a firm commitment to healthcare advancements, the company meticulously crafts a diverse portfolio of pharmaceutical formulations and active pharmaceutical ingredients (APIs), addressing a spectrum of therapeutic needs. Lyka Labs dedicates significant resources to research and development, constantly seeking to refine existing products and pioneer novel solutions that contribute to improved patient outcomes. The company's operational strategy focuses on maintaining rigorous quality control measures throughout the entire production process, from raw material sourcing to final product distribution, ensuring safety and efficacy. By fostering a culture of scientific excellence and ethical business practices, Lyka Labs is poised to continue its growth trajectory within the ever-evolving pharmaceutical sector. The company’s diverse product line demonstrates its commitment to catering to varied health and wellness requirements. Their formulations encompass a range of therapeutic areas, featuring specialized skincare solutions designed to soothe, protect, and rejuvenate. From gentle emollients and targeted topical steroids to potent antifungal and antibacterial treatments, Lyka Labs addresses common dermatological concerns with precision. Beyond skincare, the company also offers effective acne management therapies, pain relief medications, and scientifically formulated anti-aging products. Additionally, their range extends to essential personal care items such as cleansing lotions, hair care products designed to combat dandruff, and sunscreens for sun protection, reflecting a dedication to overall well-being and preventative healthcare. Lyka Labs' product development philosophy emphasizes both efficacy and safety, utilizing advanced formulations and rigorous testing protocols. Lyka Labs' strategic vision involves expanding its reach and impact within the pharmaceutical market. This expansion encompasses strengthening existing product lines through continuous innovation and strategic partnerships to introduce new and effective therapies to the market. The company places a strong emphasis on building lasting relationships with healthcare professionals and stakeholders, ensuring that their products are readily accessible to patients who need them. With a robust infrastructure, a skilled workforce, and a dedication to ethical business practices, Lyka Labs is well-positioned to navigate the complexities of the pharmaceutical industry and achieve sustainable growth. Through its commitment to quality, innovation, and patient-centric care, Lyka Labs remains a key player in shaping the future of healthcare in India and beyond.
Company Details
Key Leadership
LYKALABS Share Price: Frequently Asked Questions
What is the current share price of Lyka Labs Limited?
Lyka Labs Limited (LYKALABS) trades at ₹80.11 on NSE and BSE. Market cap ₹289.62 (Cr). Educational data only.
What is the P/E ratio of Lyka Labs Limited?
Lyka Labs Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Lyka Labs Limited?
Lyka Labs Limited has a Bull Run score of 18.9/100 based on 25+ financial parameters.
Does Lyka Labs Limited pay dividends?
Lyka Labs Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Lyka Labs Limited?
Lyka Labs Limited has ROE of -10.24%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Lyka Labs Limited?
Lyka Labs Limited has debt-to-equity of 0.52.
Is Lyka Labs Limited a good investment?
Bull Run gives Lyka Labs Limited a score of 18.9/100. This is not investment advice — consult a SEBI-registered advisor.